Market Research Logo

Metastatic Colorectal Cancer - Pipeline Review, H1 2015

Metastatic Colorectal Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Metastatic Colorectal Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Colorectal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Metastatic Colorectal Cancer Overview
Therapeutics Development
Metastatic Colorectal Cancer - Therapeutics under Development by Companies
Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Colorectal Cancer - Pipeline Products Glance
Metastatic Colorectal Cancer - Products under Development by Companies
Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes
Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development
Metastatic Colorectal Cancer - Therapeutics Assessment
Drug Profiles
Metastatic Colorectal Cancer - Recent Pipeline Updates
Metastatic Colorectal Cancer - Dormant Projects
Metastatic Colorectal Cancer - Discontinued Products
Metastatic Colorectal Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H1 2015
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2015
Metastatic Colorectal Cancer - Pipeline by AB Science, H1 2015
Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015
Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2015
Metastatic Colorectal Cancer - Pipeline by Allinky Biopharma, H1 2015
Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Angiogene Pharmaceuticals Limited, H1 2015
Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2015
Metastatic Colorectal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2015
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2015
Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2015
Metastatic Colorectal Cancer - Pipeline by Biothera, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015
Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H1 2015
Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by CureTech Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2015
Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2015
Metastatic Colorectal Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H1 2015
Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Genentech, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2015
Metastatic Colorectal Cancer - Pipeline by Hospira, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015
Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by immatics biotechnologies GmbH, H1 2015
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Incyte Corporation, H1 2015
Metastatic Colorectal Cancer - Pipeline by Kadmon Corporation, LLC, H1 2015
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Mabion SA, H1 2015
Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H1 2015
Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2015
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by MolMed S.p.A., H1 2015
Metastatic Colorectal Cancer - Pipeline by Mologen AG, H1 2015
Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2015
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2015
Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2015
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H1 2015
Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2015
Metastatic Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2015
Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H1 2015
Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015
Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Metastatic Colorectal Cancer - Dormant Projects, H1 2015
Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H1 2015
Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H1 2015
Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H1 2015
Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H1 2015
Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H1 2015
Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H1 2015
Metastatic Colorectal Cancer - Discontinued Products, H1 2015
Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Metastatic Colorectal Cancer, H1 2015
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report